Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 10/2022

07-07-2022 | Lymphoma | Letter to the Editor

First Latin America report on the diagnostic utility of the study of the MYD88 L265P gene mutation in patients with Waldenström Macroglobulinemia

Authors: F. Giuliani, M. A. Pavlovsky, I. Giere, I. Fernandez, F. Sackmann, A. Pavlovsky, G. Remaggi, J. J. Castillo

Published in: Annals of Hematology | Issue 10/2022

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Yun S, Johnson A, Okolo O, Arnold SJ, McBride A, Zhang L, Baz RC, Anwer F (2017) Waldenström macroglobulinemia: review of pathogenesis and management. Clin Lymphoma Myeloma Leuk 17(5):252–262CrossRef
2.
Kastritis E, Leblond V, Dimopoulos MA et al (2019) Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(5):860–862CrossRef
3.
Hunter ZR, Yang G, Lian Xu, Liu X, Castillo JJ, Treon SP (2017) Genomics, signaling, and treatment of Waldenström macroglobulinemia. J Clin Oncol 35(9):994–1001CrossRef
4.
Guerrera ML, Tsakmaklis N, Xu L et al (2018) MYD88 mutated and wild-type Waldenströms macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica 103(9):e408–e411CrossRef
5.
Yu X, Li W, Deng Q et al (2018) MYD88 L265P mutation in lymphoid malignancies. Cancer Res 78(10):2457–2462CrossRef
6.
Chin CK, Leslie C, Grove CS, Van Vliet C, Cheah CY (2017) The Diagnostic, prognostic, and therapeutic utility of molecular testing in a patient with Waldenstrom’s macroglobulinemia. Int J Mol Sci 18(10):2038CrossRef
7.
Xu L, Hunter ZR, Yang G et al (2013) MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 121(11):2051–2058CrossRef
8.
Gonzalez-Aguilar A, Idbaih A, Boisselier B et al (2012) Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 18(19):5203–5211CrossRef
9.
Gertz MA (2017) Waldenstrom macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. Am J Hematol 92(2):209–217CrossRef
10.
Swerdlow SH, Kuzu I, Dogan A et al (2016) The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch 468(3):259–275CrossRef
11.
Castillo JJ, Jurczyszyn A, Brozova L et al (2017) IgM myeloma: a multicenter retrospective study of 134 patients. Am J Hematol 92(8):746–751CrossRef
12.
Schuster SR, Rajkumar SV, Dispenzieri A et al (2010) IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom’s macroglobulinemia. Am J Hematol 85:853–855CrossRef
Metadata
Title
First Latin America report on the diagnostic utility of the study of the MYD88 L265P gene mutation in patients with Waldenström Macroglobulinemia
Authors
F. Giuliani
M. A. Pavlovsky
I. Giere
I. Fernandez
F. Sackmann
A. Pavlovsky
G. Remaggi
J. J. Castillo
Publication date
07-07-2022
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 10/2022
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-022-04910-y

Other articles of this Issue 10/2022

Annals of Hematology 10/2022 Go to the issue

Letter to the Editor

Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type

Letter to the Editor

Forodesine maintenance therapy for newly diagnosed peripheral T-cell lymphoma: a single-institutional, observational, retrospective analysis

Letter to the Editor

Can we restart the rituximab after remission of rituximab-induced interstitial lung disease in malignant lymphoma?

Original Article

Functional association of NR4A3 downregulation with impaired differentiation in myeloid leukemogenesis

Original Article

Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies

Original Article

Maternal and fetal outcomes of pregnancy occurring after a diagnosis of immune-mediated thrombotic thrombocytopenic purpura
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits